SI3061760T1 - Devterirani derivati benzokinolizina kot inhibitorji vezikularnega monoaminskega transporterja 2 - Google Patents
Devterirani derivati benzokinolizina kot inhibitorji vezikularnega monoaminskega transporterja 2 Download PDFInfo
- Publication number
- SI3061760T1 SI3061760T1 SI200931797T SI200931797T SI3061760T1 SI 3061760 T1 SI3061760 T1 SI 3061760T1 SI 200931797 T SI200931797 T SI 200931797T SI 200931797 T SI200931797 T SI 200931797T SI 3061760 T1 SI3061760 T1 SI 3061760T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- use according
- deuterium
- enrichment
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (13)
- Devterirani derivati benzokinolizina kot inhibitorji vezikulamega monoaminskega transporterja 2 Patentni zahtevki1. Spojina,ali njena sol za uporabo v zdravljenju kronične hiperkinetične motnje gibanja.
- 2. Spojina za uporabo po zahtevku 1, kjer je omenjena kronična hiperkinetična motnja gibanja Tourettov sindrom.
- 3. Spoj ina za uporabo po zahtevku 1, kjer je omenjena kronična hiperkinetična motnja gibanja tardivna diskinezija.
- 4. Spojina za uporabo po zahtevku 1, kjer je omenjena kronična hiperkinetična motnja gibanja tik.
- 5. Spojina za uporabo po zahtevku 1 v kombinaciji z dodatnim terapevtskim sredstvom.
- 6. Spojina za uporabo po zahtevku 5, kjer je omenjeno dodatno terapevtsko sredstvo izbrano iz skupine, ki vsebuje olanzapin in pimozid.
- 7. Spojina za uporabo po zahtevku 6, kjer je omenjeno dodatno terapevtsko sredstvo izbrano iz skupine, ki vsebuje benzodiazepine in antipsihotike.
- 8. Spojina za uporabo po zahtevku 7, kjer je omenjeni benzodiazepin izbran iz skupine, ki vsebuje alprazolam, adinazolam, bromazepam, kamazepam, klobazam, klonazepam, clotiazepam, kloksazolam, diazepam, etil loflazepat, estizolam, fludiazepam, flunitrazepam, halazepam, ketazolam, lorazepam, medazepam, dazolam, nitrazepam, nordazepam, oksazepam, kalijev klorazepat, pinazepam, prazepam, tofisopam, triazolam, temazepam in klordiazepoksid.
- 9. Spojina za uporabo po zahtevku 7, kjer je omenjeni antipsihotik izbran iz skupin, ki vsebuje klorpromazin, levomepromazin, promazi, acepromazin, triflupromazin, ciamemazin, klorproetazin, diksirazin, flufenazin, perfenazin, proklorperazin, tiopropazat, trifluoperazin, acetofenazin, tioproperazin, butaperazin, perazin, periciazin, tioridazin, mesoridazin, pipotiazin, haloperidol, trifluperidol, melperon, moperon, pipamperon, bromperidol, benperidol, droperidol, fluanison, oksipertin, molindon, sertindol, ziprazidon, flupentiksol, clopentiksol, klorprotiksen, tiotiksen, zuklopentiksol, fluspirilen, pimozid, penfluridol, loksapin, klozapin, olanzapin, kvetiapin, tetrabenazin, sulpirid, sultoprid, tiaprid, remoksiprid, amisulprid, veraliprid, levosulpirid, litij, protipendil, risperidon, klotiapin, mozapramin, zotepin, pripiprazol in paliperidon.
- 10. Spojina za uporabo po zahtevku 1, kjer ima vsak položaj, kije predstavljen kot D obogatitev z devterijem ne manj kot približno 10%.
- 11. Spojina za uporabo po zahtevku 1, kjer ima vsak položaj, kije predstavljen kot D obogatitev z devterijem ne manj kot približno 50%.
- 12. Spojina za uporabo po zahtevku 1, kjer ima vsak položaj, kije predstavljen kot D obogatitev z devterijem ne manj kot približno 90%.
- 13. Spojina za uporabo po zahtevku 1, kjer ima vsak položaj, kije predstavljen kot D obogatitev z devterijem ne manj kot približno 98%.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9789608P | 2008-09-18 | 2008-09-18 | |
EP15185548.3A EP3061760B1 (en) | 2008-09-18 | 2009-09-18 | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3061760T1 true SI3061760T1 (sl) | 2018-04-30 |
Family
ID=42107127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931797T SI3061760T1 (sl) | 2008-09-18 | 2009-09-18 | Devterirani derivati benzokinolizina kot inhibitorji vezikularnega monoaminskega transporterja 2 |
Country Status (20)
Country | Link |
---|---|
US (15) | US8524733B2 (sl) |
EP (4) | EP2326643B1 (sl) |
JP (3) | JP5616345B2 (sl) |
CN (2) | CN104311552A (sl) |
AU (1) | AU2009303758B8 (sl) |
BR (1) | BRPI0913457B8 (sl) |
CA (2) | CA2736409C (sl) |
CY (1) | CY1120060T1 (sl) |
DK (2) | DK3061760T3 (sl) |
ES (4) | ES2896678T3 (sl) |
HK (3) | HK1186728A1 (sl) |
HR (1) | HRP20180239T1 (sl) |
HU (1) | HUE038158T2 (sl) |
LT (1) | LT3061760T (sl) |
NO (1) | NO3061760T3 (sl) |
NZ (1) | NZ591615A (sl) |
PL (1) | PL3061760T3 (sl) |
PT (1) | PT3061760T (sl) |
SI (1) | SI3061760T1 (sl) |
WO (1) | WO2010044981A2 (sl) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2326643B1 (en) * | 2008-09-18 | 2013-05-29 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
ES2444543T3 (es) * | 2009-11-10 | 2014-02-25 | Pfizer Inc | Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa |
CN103003275A (zh) * | 2010-06-01 | 2013-03-27 | 奥斯拜客斯制药有限公司 | Vmat2的苯并喹啉酮抑制剂 |
DK2608762T4 (da) | 2010-08-27 | 2020-07-20 | Sienna Biopharmaceuticals Inc | Sammensætninger og fremgangsmåder til målrettet varmemodulering |
US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
CN116768882A (zh) * | 2012-09-18 | 2023-09-19 | 奥斯拜客斯制药有限公司 | 化合物、及其药物组合物及治疗方法 |
EP2906286B1 (en) | 2012-10-11 | 2017-06-14 | Nanocomposix, Inc. | Silver nanoplate compositions and methods |
MX2015009719A (es) | 2013-01-31 | 2016-08-08 | Auspex Pharmaceuticals Inc | Inhibidores benzoquinolona de vmat2. |
US20160207917A1 (en) * | 2013-09-27 | 2016-07-21 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
JP2017503756A (ja) * | 2013-11-22 | 2017-02-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | 異常な筋活動を処置する方法 |
WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
JP6542222B2 (ja) | 2013-12-03 | 2019-07-10 | オースペックス ファーマシューティカルズ インコーポレイテッド | ベンゾキノリン化合物の製造方法 |
MX2016009817A (es) * | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
CA2938244A1 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharamaceuticals, Inc. | Novel pharmaceutical formulations |
EP3102239A1 (en) * | 2014-02-07 | 2016-12-14 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
PL3139925T3 (pl) | 2014-05-06 | 2022-03-21 | Neurocrine Biosciences, Inc. | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu |
MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
CN114788824A (zh) * | 2015-03-06 | 2022-07-26 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
US20180071024A1 (en) * | 2015-03-20 | 2018-03-15 | Sienna Biopharmaceuticals, Inc. | Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles |
MA43116B1 (fr) | 2015-10-30 | 2021-04-30 | Neurocrine Biosciences Inc | Ditosylate de valbénazine et polymorphes associés |
HRP20220621T1 (hr) | 2015-12-23 | 2022-06-24 | Neurocrine Biosciences, Inc. | Postupak sinteze za proizvodnju (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
US10479787B2 (en) | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
WO2017221169A1 (en) | 2016-06-24 | 2017-12-28 | Lupin Limited | Premixes of deutetrabenazine |
CN107936008B (zh) * | 2016-10-13 | 2022-06-14 | 泰州华元医药科技有限公司 | 氘代化合物及其医药用途 |
EP4400171A2 (en) | 2016-12-02 | 2024-07-17 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
JP7199359B2 (ja) | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 特定のvmat2インヒビターを投与するための方法 |
JP2020508337A (ja) | 2017-02-27 | 2020-03-19 | サンド・アクチエンゲゼルシヤフト | バルベナジン塩の結晶形態 |
WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
WO2018170214A1 (en) | 2017-03-15 | 2018-09-20 | Zhang Chengzi | Analogs of deutetrabenazine, their preparation and use |
JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
US10786495B2 (en) * | 2017-10-10 | 2020-09-29 | The Regents Of The University Of California | Vesicular monoamine transporter 2 inhibitors for treating stuttering |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
CA3077149A1 (en) | 2017-10-10 | 2019-04-18 | Neurocrine Biosciences, Inc. | Methods for the administration of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2yl ester and salts thereof |
WO2019130252A2 (en) | 2017-12-29 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing deutetrabenazine |
WO2019147934A1 (en) | 2018-01-29 | 2019-08-01 | Sackner Bernstein Jonathan | Methods for dopamine modulation in human neurologic diseases |
WO2019150387A1 (en) * | 2018-02-01 | 2019-08-08 | Alaparthi Lakshmi Prasad | A novel process for preparation of deutetrabenazine |
WO2019166962A1 (en) | 2018-03-01 | 2019-09-06 | Mylan Laboratories Ltd | Deutetrabenazine polymorphs and methods for their preparation |
BR112020021700A2 (pt) * | 2018-04-25 | 2021-01-26 | Shinkei Therapeutics Llc | dispositivo de distribuição transdérmica de tetrabenazina |
CA3043075A1 (en) | 2018-05-14 | 2019-11-14 | Apotex Inc | Novel crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2 |
BR112020024018A2 (pt) | 2018-06-14 | 2021-02-23 | Neurocrine Biosciences Inc. | compostos inibidores de vmat2, composições e métodos relacionados a eles |
CN108794337A (zh) * | 2018-07-10 | 2018-11-13 | 上海华堇生物技术有限责任公司 | 一种3,4-二羟基-β-硝基苯乙烯的新制备方法 |
CA3104693A1 (en) | 2018-08-15 | 2020-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
CA3116198A1 (en) | 2018-10-18 | 2020-04-23 | Oncopeptides Ab | Compounds containing deuterium |
US11324732B2 (en) | 2018-12-13 | 2022-05-10 | Auspex Pharmaceuticals, Inc. | Methods for the treatment of dyskinesia in cerebral palsy |
CA3130741A1 (en) | 2019-02-22 | 2020-08-27 | Ihi Corporation | Thrust foil bearing, and method for manufacturing base plate of thrust foil bearing |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
DK4153136T3 (da) | 2020-06-10 | 2024-03-25 | Auspex Pharmaceuticals Inc | Osmotiske doseringsformer, som omfatter deutetrabenazin, og fremgangsmåder til anvendelse deraf |
KR20230067636A (ko) | 2020-09-17 | 2023-05-16 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진을 포함하는 다중미립자 제형 |
AU2021362683A1 (en) | 2020-10-12 | 2023-06-01 | Auspex Pharmaceuticals, Inc. | Gastro retentive dosage forms comprising deutetrabenazine |
KR20230160308A (ko) | 2021-03-22 | 2023-11-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Vmat2 억제제 및 사용 방법 |
MX2023014827A (es) | 2021-06-30 | 2024-01-15 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento complementario de la esquizofrenia. |
EP4401707A1 (en) | 2021-09-17 | 2024-07-24 | Auspex Pharmaceuticals, Inc. | Multiparticulate dosage forms comprising deutetrabenazine |
WO2023172849A1 (en) | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
WO2023240186A1 (en) | 2022-06-08 | 2023-12-14 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830993A (en) | 1958-04-15 | Quinolizine derivatives | ||
US3045021A (en) | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
US4316897A (en) | 1980-09-10 | 1982-02-23 | Hoffmann-La Roche Inc. | Method of lowering serum prolactin |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
EP0751926B1 (en) | 1994-03-25 | 2007-09-12 | Isotechnika,Inc. | Enhancement of the efficacy of drugs by deuteration |
US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
ATE234299T1 (de) | 1999-12-03 | 2003-03-15 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
EP1134290A3 (en) | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
AU2004292966A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
US20080033011A1 (en) | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
MX2008014064A (es) | 2006-05-02 | 2009-06-12 | Univ Pennsylvania | Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes. |
ES2402220T3 (es) | 2006-11-08 | 2013-04-29 | Neurocrine Biosciences, Inc. | Compuestos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-ol sustituidos y métodos relacionados con los mismos |
DK2078026T3 (da) | 2006-11-21 | 2012-04-30 | Rigel Pharmaceuticals Inc | Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf |
WO2008112278A2 (en) | 2007-03-12 | 2008-09-18 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
DK2173344T3 (en) | 2007-06-29 | 2016-07-25 | Clarencew Pty Ltd | TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEURO PSYCHIATRIC DISORDERS USING ocular administration |
WO2009124357A1 (en) | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
EP2326643B1 (en) * | 2008-09-18 | 2013-05-29 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
US20100113496A1 (en) | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
JP2013501810A (ja) | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル(バルバドス)エスアールエル | 医薬組成物 |
KR20120120970A (ko) | 2010-02-24 | 2012-11-02 | 오스펙스 파마슈티칼스, 인코포레이티드 | 티로신 키나아제의 트리메톡시페닐 저해제 |
CN103003275A (zh) | 2010-06-01 | 2013-03-27 | 奥斯拜客斯制药有限公司 | Vmat2的苯并喹啉酮抑制剂 |
-
2009
- 2009-09-18 EP EP09820972.9A patent/EP2326643B1/en active Active
- 2009-09-18 NZ NZ591615A patent/NZ591615A/en unknown
- 2009-09-18 SI SI200931797T patent/SI3061760T1/sl unknown
- 2009-09-18 CA CA2736409A patent/CA2736409C/en active Active
- 2009-09-18 BR BRPI0913457A patent/BRPI0913457B8/pt active IP Right Grant
- 2009-09-18 PL PL15185548T patent/PL3061760T3/pl unknown
- 2009-09-18 JP JP2011527995A patent/JP5616345B2/ja active Active
- 2009-09-18 EP EP17199778.6A patent/EP3345905B1/en active Active
- 2009-09-18 CN CN201410524867.7A patent/CN104311552A/zh active Pending
- 2009-09-18 CN CN200980141378.0A patent/CN102186848B/zh active Active
- 2009-09-18 DK DK15185548.3T patent/DK3061760T3/en active
- 2009-09-18 ES ES17199778T patent/ES2896678T3/es active Active
- 2009-09-18 ES ES09820972T patent/ES2425623T3/es active Active
- 2009-09-18 PT PT151855483T patent/PT3061760T/pt unknown
- 2009-09-18 ES ES15185548.3T patent/ES2652289T3/es active Active
- 2009-09-18 ES ES13160950.5T patent/ES2563820T3/es active Active
- 2009-09-18 EP EP13160950.5A patent/EP2610254B1/en not_active Not-in-force
- 2009-09-18 US US12/562,621 patent/US8524733B2/en active Active
- 2009-09-18 NO NO15185548A patent/NO3061760T3/no unknown
- 2009-09-18 LT LTEP15185548.3T patent/LT3061760T/lt unknown
- 2009-09-18 DK DK09820972.9T patent/DK2326643T3/da active
- 2009-09-18 CA CA2972242A patent/CA2972242A1/en not_active Abandoned
- 2009-09-18 EP EP15185548.3A patent/EP3061760B1/en active Active
- 2009-09-18 AU AU2009303758A patent/AU2009303758B8/en active Active
- 2009-09-18 WO PCT/US2009/057480 patent/WO2010044981A2/en active Application Filing
- 2009-09-18 HU HUE15185548A patent/HUE038158T2/hu unknown
-
2013
- 2013-07-03 US US13/934,960 patent/US20130296360A1/en not_active Abandoned
- 2013-12-20 HK HK13114111.0A patent/HK1186728A1/zh not_active IP Right Cessation
-
2014
- 2014-03-25 US US14/225,010 patent/US20140206713A1/en not_active Abandoned
- 2014-03-25 US US14/224,883 patent/US20140206712A1/en not_active Abandoned
- 2014-08-08 US US14/454,911 patent/US20140350044A1/en not_active Abandoned
- 2014-09-11 JP JP2014185634A patent/JP5970037B2/ja active Active
- 2014-10-15 US US14/515,047 patent/US20150080427A1/en not_active Abandoned
-
2015
- 2015-07-23 US US14/807,364 patent/US20150328207A1/en not_active Abandoned
-
2016
- 2016-02-11 US US15/041,571 patent/US20160158220A1/en not_active Abandoned
- 2016-04-08 US US15/094,517 patent/US20160220558A1/en not_active Abandoned
- 2016-07-08 JP JP2016136178A patent/JP6138322B2/ja active Active
- 2016-09-01 US US15/254,912 patent/US20160367548A1/en not_active Abandoned
- 2016-09-06 US US15/257,372 patent/US20160375005A1/en not_active Abandoned
- 2016-09-21 HK HK16111056.0A patent/HK1222853A1/zh unknown
-
2017
- 2017-02-28 US US15/445,402 patent/US20170166562A1/en not_active Abandoned
-
2018
- 2018-02-07 CY CY20181100152T patent/CY1120060T1/el unknown
- 2018-02-07 HR HRP20180239TT patent/HRP20180239T1/hr unknown
- 2018-12-05 US US16/210,077 patent/US20190375746A1/en not_active Abandoned
-
2019
- 2019-01-08 HK HK19100241.6A patent/HK1257880A1/zh unknown
-
2020
- 2020-03-17 US US16/821,067 patent/US20200347048A1/en not_active Abandoned
-
2021
- 2021-11-05 US US17/519,922 patent/US20220267317A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3061760T1 (sl) | Devterirani derivati benzokinolizina kot inhibitorji vezikularnega monoaminskega transporterja 2 | |
JP2015537003A5 (sl) | ||
HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
CA2950203C (en) | Enteric soft capsule compositions | |
US10182992B2 (en) | Abuse-deterrent controlled release formulations | |
RU99122597A (ru) | Новые терапевтические комбинации миртазапина и антипсихотических средств для лечения или профилактики психотических расстройств | |
Lee et al. | Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study | |
CN1226036C (zh) | 用于治疗或预防精神病的、米尔塔扎平和抗精神病药的药物组合物 | |
Kapil et al. | Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels | |
NZ592437A (en) | A dosage form comprising tapentadol and an opioid antagonist | |
RU2016135930A (ru) | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение | |
JP2009525343A5 (sl) | ||
CN101678018A (zh) | 用于治疗精神分裂症的(硫代)-氨甲酰基-环己烷衍生物和方法 | |
ES2968827T3 (es) | Dispositivo de administración transdérmica de tetrabenazina | |
Schreiber et al. | Beneficial effect of risperidone on sleep disturbance and psychosis following | |
Chidiac et al. | Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.) | |
ES2387575T3 (es) | Sistema de aplicación para un parche que contiene un principio activo y un medio de regulación del suministro del principio activo | |
HRP20210236T1 (hr) | Formulacije zadržanog otpuštanja lorazepama | |
US20180071278A1 (en) | Anti-overingestion dosage forms | |
US10335405B1 (en) | Non-burst releasing pharmaceutical composition | |
US20160199368A1 (en) | Abuse-deterrent opioids | |
Chiu et al. | Amisulpride augmentation of clozapine in refractory schizophrenia | |
Green et al. | General approach to and summary of the guideline for the management of atopic dermatitis: CME-summary | |
AU2020370073A1 (en) | Tetrabenazine transdermal delivery device | |
Mendhekar et al. | Clozapine-induced tardive dyskinesia and hypothyroidism |